Developer docs
API playgroundTry for free, no card

Search company profiles

REGENE GLOBAL

Full company profile

uuid005743s

Namestring
REGENE GLOBAL
Legal namestring
REGENE GLOBAL, SOCIEDAD ANÓNIMA DE CAPITAL VARIABLE
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Regene Global is a Mexico-based regenerative medicine company founded in 2017 in Zapopan, Jalisco, that has scaled from a 5-person local biologics distributor to approximately 100 collaborators operating an integrated regenerative medicine ecosystem. The company develops, manufactures and distributes cell-based therapies including mesenchymal stem cells, DEZAWA MUSE CELLS™ (pluripotent stem cells licensed from MUSECell Innovations™), therapeutic exosomes, autologous growth factors, bioactive scaffolds, peptides, regenerative capsules and IV serotherapy products. Manufacturing is performed at its own biotechnological laboratory, Regene Labs, operating under GMP standards and ISO certification.

The commercial model is anchored on a global network of authorized healthcare centers and international distributors that administer Regene therapies in clinical settings, supplemented by direct-to-consumer e-commerce for cosmetic and supplement products. Regene Academy operates as a parallel revenue line and adoption engine, providing certification and training programs to healthcare professionals in regenerative medicine applications. The primary customer segments are licensed clinicians and clinics serving patients in dermatology, orthopedics, aesthetic medicine, neurology, sports medicine, and chronic wound treatment, with end patients as the indirect consumer base. Disclosed pricing is quote-based for therapeutic products through authorized centers; consumer and cosmetic pricing is sold through the online storefront.

Beyond therapeutics, Regene Global operates Regene Cosmetics as a consumer-facing sub-brand and hosts the Regene Pulse industry conference series, with the 2025 edition held at Hard Rock Hotel Guadalajara. No external investors, funding rounds, or parent company have been disclosed; the company is privately held under Mexican law as a Sociedad Anónima de Capital Variable (S.A. de C.V.), with no public revenue figures available. The 2025 Fluxx Award "Sustainable Finance Innovator of the Year" was granted to the founder for prior financial frameworks designed at Regene Global, signaling leadership involvement in capital strategy beyond the operating company.

Short descriptiontext

Regene Global is a Mexico-based regenerative medicine company founded in 2017 that develops and distributes stem cell therapies, exosomes, growth factors, and bioactive scaffolds under GMP/ISO standards. It serves licensed clinicians and clinics through a global authorized healthcare center network and earns recurring revenue from its Regene Academy training and certification platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersZapopan, Jalisco, Mexico
HQ citystring
Zapopan, Jalisco
HQ countrystring
Mexico
HQ regionstring
Latin America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine, stem cell therapy, exosome therapeutics, biotechnology manufacturing, medical aesthetics
Industry4 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine Biotechnology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Biotechnology Products and Therapies
TypeOne Time License
Description

Sale of regenerative medical products including mesenchymal stem cells, exosomes, growth factors, implants, scaffolds, peptides, and serotherapy products. Primarily distributed through authorized healthcare centers and distributors worldwide with online sales component.

regeneglobal.com
2Education and Certification
TypeSubscription Recurring
Description

Regene Academy provides training and certification programs for healthcare professionals in regenerative medicine applications, creating a revenue stream while also driving product adoption.

regeneglobal.com
3Cosmetic Products
TypeOne Time License
Description

Sale of Regene Cosmetics products through their e-commerce and distributor network.

regeneglobal.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Regene Pulse 2025 Event
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Event ticket priced at $1500 USD for full-day conference at Hard Rock Hotel Guadalajara

regeneglobal.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Regene Labs
Description

Biotechnological laboratory developing regenerative therapies with mesenchymal stem cells, therapeutic exosomes, and autologous growth factors under GMP and ISO standards.

regeneglobal.com
+3 more records
Core offering1 text field

Regene Global develops, manufactures, and distributes regenerative medicine biotechnological products, including mesenchymal stem cells, therapeutic exosomes, autologous growth factors, bioactive scaffolds, peptides, regenerative capsules, and IV serotherapy under GMP standards and ISO certification. The company operates an integrated ecosystem spanning its own laboratory (Regene Labs), a professional education and certification platform (Regene Academy), and a consumer cosmetics line (Regene Cosmetics), distributing through authorized healthcare centers, international distributors, and direct online channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 80%+ pain reduction in patients with grade 3 osteoarthritis at 6 months
+2 more records
Product overview1 text field

Regene Global is a regenerative medicine company operating as a platform with multiple integrated offerings: Regene Labs (biotechnological laboratory) develops and manufactures therapies under GMP/ISO standards, while Regene Academy provides education and certification for healthcare professionals. The core product is DEZAWA MUSE CELLS®, pluripotent stem cells licensed from MUSECell Innovations™ for therapeutic applications. The company also offers a portfolio of regenerative products including mesenchymal stem cells, therapeutic exosomes, autologous growth factors, bioactive scaffolds, peptides, peptones, capsules, and IV serotherapy. Founded in 2017 in Guadalajara, Mexico, the company has grown from 5 employees to approximately 100 collaborators with global distributor presence.

Product and service10 records
1DEZAWA MUSE CELLS®
CategoryRegenerative Cellular Therapy
2Mesenchymal Stem Cells (Células Madre Mesenquimales)
CategoryRegenerative Cellular Therapy
3Therapeutic Exosomes (Exosomas Terapéuticos)
CategoryRegenerative Cellular Therapy
4Autologous Growth Factors (Factores de Crecimiento Autólogos)
CategoryRegenerative Biologics
5Bioactive Scaffolds (Andamios Bioactivos)
CategoryRegenerative Biologics
6Peptides and Peptones (Péptidos y Peptonas)
CategoryRegenerative Biologics
7Regenerative Capsules (Cápsulas Regenerativas)
CategoryRegenerative Wellness
8IV Serotherapy (Sueroterapia)
CategoryRegenerative Wellness
9Regene Academy Education and Certification Programs
CategoryProfessional Education Services
10Regene Cosmetics Product Line
CategoryMedical Aesthetics
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Pluristem Therapeutics
TypeDirect peer
Description

Pluristem develops placenta-derived cell therapies and exosome products for regenerative indications, closely aligned with Regene Global's allogeneic cell and exosome platform strategy.

TypeEmerging player
Description

BioXcellerator operates regenerative medicine clinics in Colombia and other Latin American markets offering stem cell and exosome therapies, comparable as an emerging regional peer in the medical-tourism regenerative space.

TypeDirect peer
Description

Cytori developed cell therapy devices and adipose-derived regenerative cell products for orthopedic and wound healing indications, an overlapping regenerative medicine peer with similar clinical positioning.

TypeDirect peer
Description

Mesoblast develops mesenchymal stem cell (MSC)-based therapies for inflammatory and degenerative diseases, directly comparable to Regene Global's MSC and exosome offerings for orthopedic and inflammatory indications.

TypeBroad incumbent
Description

Galderma is a global dermatology and aesthetics incumbent; its regenerative aesthetics portfolio and exosome/biologic skincare R&D overlap with Regene Cosmetics and Regene Global's dermatology use cases.

TypeDirect peer
Description

Medipost commercializes Cartistem (umbilical cord blood-derived MSCs for cartilage regeneration) and other stem cell therapies, a directly comparable regenerative medicine peer with GMP manufacturing and global distribution.

TypeDirect peer
Description

Lineage develops allogeneic cell therapies for orthopedic, ophthalmic, and neurological indications, directly comparable to Regene Global's MSC-based orthopedic and tissue regeneration focus.

8Athersys
TypeDirect peer
Description

Athersys develops MultiStem, an allogeneic stem cell platform for inflammatory, neurological, and cardiovascular indications — comparable in mechanism and clinical positioning to Regene Global's MSC and MUSE cell therapies.

TypeBroad incumbent
Description

BlueRock Therapeutics (Bayer subsidiary) develops iPSC-derived cell therapies for regenerative indications including cardiology and neurology, a broad incumbent with significant capital and clinical infrastructure competing in adjacent regenerative categories.

TypeRegional player
Description

Celltex is a Houston-based autologous stem cell banking and therapy company serving primarily US and Latin American markets, comparable as a regional regenerative medicine player with cross-border Mexico/US operations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

REGENE GLOBAL

Regenerative Medicine Biotechnologyregeneglobal.com

Regene Global is a Mexico-based regenerative medicine company founded in 2017 that develops and distributes stem cell therapies, exosomes, growth factors, and bioactive scaffolds under GMP/ISO standards. It serves licensed clinicians and clinics through a global authorized healthcare center network and earns recurring revenue from its Regene Academy training and certification platform.

What REGENE GLOBAL does

Regene Global is a Mexico-based regenerative medicine company founded in 2017 in Zapopan, Jalisco, that has scaled from a 5-person local biologics distributor to approximately 100 collaborators operating an integrated regenerative medicine ecosystem. The company develops, manufactures and distributes cell-based therapies including mesenchymal stem cells, DEZAWA MUSE CELLS™ (pluripotent stem cells licensed from MUSECell Innovations™), therapeutic exosomes, autologous growth factors, bioactive scaffolds, peptides, regenerative capsules and IV serotherapy products. Manufacturing is performed at its own biotechnological laboratory, Regene Labs, operating under GMP standards and ISO certification.

The commercial model is anchored on a global network of authorized healthcare centers and international distributors that administer Regene therapies in clinical settings, supplemented by direct-to-consumer e-commerce for cosmetic and supplement products. Regene Academy operates as a parallel revenue line and adoption engine, providing certification and training programs to healthcare professionals in regenerative medicine applications. The primary customer segments are licensed clinicians and clinics serving patients in dermatology, orthopedics, aesthetic medicine, neurology, sports medicine, and chronic wound treatment, with end patients as the indirect consumer base. Disclosed pricing is quote-based for therapeutic products through authorized centers; consumer and cosmetic pricing is sold through the online storefront.

Beyond therapeutics, Regene Global operates Regene Cosmetics as a consumer-facing sub-brand and hosts the Regene Pulse industry conference series, with the 2025 edition held at Hard Rock Hotel Guadalajara. No external investors, funding rounds, or parent company have been disclosed; the company is privately held under Mexican law as a Sociedad Anónima de Capital Variable (S.A. de C.V.), with no public revenue figures available. The 2025 Fluxx Award "Sustainable Finance Innovator of the Year" was granted to the founder for prior financial frameworks designed at Regene Global, signaling leadership involvement in capital strategy beyond the operating company.

REGENE GLOBAL firmographics

Firmographics
Name
REGENE GLOBAL
Legal name
REGENE GLOBAL, SOCIEDAD ANÓNIMA DE CAPITAL VARIABLE
Website
https://regeneglobal.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Regene Global is a Mexico-based regenerative medicine company founded in 2017 that develops and distributes stem cell therapies, exosomes, growth factors, and bioactive scaffolds under GMP/ISO standards. It serves licensed clinicians and clinics through a global authorized healthcare center network and earns recurring revenue from its Regene Academy training and certification platform.
Ownership category
akta.pro rank

REGENE GLOBAL industry classification

Industry
Product category
Regenerative Medicine Biotechnology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative medicine
  • Stem cell therapy
  • Exosome therapeutics
  • Biotechnology manufacturing
  • Medical aesthetics

Where REGENE GLOBAL is headquartered

Location

Headquarters

HQ city
Zapopan, Jalisco
HQ country
Mexico
HQ region
Latin America

Offices2 records

Markets served

REGENE GLOBAL business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biotechnology Products and Therapies: Sale of regenerative medical products including mesenchymal stem cells, exosomes, growth factors, implants, scaffolds, peptides, and serotherapy products. Primarily distributed through authorized healthcare centers and distributors worldwide with online sales component.
  2. Education and Certification: Regene Academy provides training and certification programs for healthcare professionals in regenerative medicine applications, creating a revenue stream while also driving product adoption.
  3. Cosmetic Products: Sale of Regene Cosmetics products through their e-commerce and distributor network.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goRegene Pulse 2025 Event

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

REGENE GLOBAL product offering

Product offering

Core offering

Regene Global develops, manufactures, and distributes regenerative medicine biotechnological products, including mesenchymal stem cells, therapeutic exosomes, autologous growth factors, bioactive scaffolds, peptides, regenerative capsules, and IV serotherapy under GMP standards and ISO certification. The company operates an integrated ecosystem spanning its own laboratory (Regene Labs), a professional education and certification platform (Regene Academy), and a consumer cosmetics line (Regene Cosmetics), distributing through authorized healthcare centers, international distributors, and direct online channels.

Product overview

Regene Global is a regenerative medicine company operating as a platform with multiple integrated offerings: Regene Labs (biotechnological laboratory) develops and manufactures therapies under GMP/ISO standards, while Regene Academy provides education and certification for healthcare professionals. The core product is DEZAWA MUSE CELLS®, pluripotent stem cells licensed from MUSECell Innovations™ for therapeutic applications. The company also offers a portfolio of regenerative products including mesenchymal stem cells, therapeutic exosomes, autologous growth factors, bioactive scaffolds, peptides, peptones, capsules, and IV serotherapy. Founded in 2017 in Guadalajara, Mexico, the company has grown from 5 employees to approximately 100 collaborators with global distributor presence.

Differentiator

Problem solved

Functional benefit

Brands

  • Regene Labs: Biotechnological laboratory developing regenerative therapies with mesenchymal stem cells, therapeutic exosomes, and autologous growth factors under GMP and ISO standards.
  • Regene Academy
  • Regene Cosmetics
  • DEZAWA MUSE CELLS®

Products and services

  • DEZAWA MUSE CELLS®
  • Mesenchymal Stem Cells (Células Madre Mesenquimales)
  • Therapeutic Exosomes (Exosomas Terapéuticos)
  • Autologous Growth Factors (Factores de Crecimiento Autólogos)
  • Bioactive Scaffolds (Andamios Bioactivos)
  • Peptides and Peptones (Péptidos y Peptonas)
  • Regenerative Capsules (Cápsulas Regenerativas)
  • IV Serotherapy (Sueroterapia)
  • Regene Academy Education and Certification Programs
  • Regene Cosmetics Product Line

Quantifiable outcome

  • 80%+ pain reduction in patients with grade 3 osteoarthritis at 6 months
  • +2 more outcomes

Companies that use REGENE GLOBAL

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

REGENE GLOBAL technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

REGENE GLOBAL partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

REGENE GLOBAL competitors and assessment

Company assessment

Direct peers

  • Pluristem Therapeutics: Pluristem develops placenta-derived cell therapies and exosome products for regenerative indications, closely aligned with Regene Global's allogeneic cell and exosome platform strategy.
  • Cytori Therapeutics: Cytori developed cell therapy devices and adipose-derived regenerative cell products for orthopedic and wound healing indications, an overlapping regenerative medicine peer with similar clinical positioning.
  • Mesoblast: Mesoblast develops mesenchymal stem cell (MSC)-based therapies for inflammatory and degenerative diseases, directly comparable to Regene Global's MSC and exosome offerings for orthopedic and inflammatory indications.
  • Medipost: Medipost commercializes Cartistem (umbilical cord blood-derived MSCs for cartilage regeneration) and other stem cell therapies, a directly comparable regenerative medicine peer with GMP manufacturing and global distribution.
  • Lineage Cell Therapeutics: Lineage develops allogeneic cell therapies for orthopedic, ophthalmic, and neurological indications, directly comparable to Regene Global's MSC-based orthopedic and tissue regeneration focus.
  • Athersys: Athersys develops MultiStem, an allogeneic stem cell platform for inflammatory, neurological, and cardiovascular indications — comparable in mechanism and clinical positioning to Regene Global's MSC and MUSE cell therapies.

Emerging players

  • BioXcellerator: BioXcellerator operates regenerative medicine clinics in Colombia and other Latin American markets offering stem cell and exosome therapies, comparable as an emerging regional peer in the medical-tourism regenerative space.

Broad incumbents

  • Galderma: Galderma is a global dermatology and aesthetics incumbent; its regenerative aesthetics portfolio and exosome/biologic skincare R&D overlap with Regene Cosmetics and Regene Global's dermatology use cases.
  • BlueRock Therapeutics: BlueRock Therapeutics (Bayer subsidiary) develops iPSC-derived cell therapies for regenerative indications including cardiology and neurology, a broad incumbent with significant capital and clinical infrastructure competing in adjacent regenerative categories.

Regional players

  • Celltex Therapeutics: Celltex is a Houston-based autologous stem cell banking and therapy company serving primarily US and Latin American markets, comparable as a regional regenerative medicine player with cross-border Mexico/US operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

REGENE GLOBAL social profiles

Digital presence

REGENE GLOBAL compliance and trust

Trust signal

Compliance1 record

REGENE GLOBAL financial estimates

Financial estimate

Revenue estimate

Valuation estimate

REGENE GLOBAL leadership team

Management profile

Number of profiles

REGENE GLOBAL subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

REGENE GLOBAL funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

REGENE GLOBAL M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about REGENE GLOBAL

What does REGENE GLOBAL do?

Regene Global develops, manufactures, and distributes regenerative medicine biotechnological products, including mesenchymal stem cells, therapeutic exosomes, autologous growth factors, bioactive scaffolds, peptides, regenerative capsules, and IV serotherapy under GMP standards and ISO certification. The company operates an integrated ecosystem spanning its own laboratory (Regene Labs), a professional education and certification platform (Regene Academy), and a consumer cosmetics line (Regene Cosmetics), distributing through authorized healthcare centers, international distributors, and direct online channels.

Is REGENE GLOBAL a public or private company?

REGENE GLOBAL is a private company. It is classified as unknown and is currently operating.

When was REGENE GLOBAL founded?

REGENE GLOBAL was founded in 2017. It employs 11 to 50 people.

Where is REGENE GLOBAL based?

REGENE GLOBAL is headquartered in Zapopan, Jalisco, Mexico, in the Latin America region.

How does REGENE GLOBAL make money?

Three revenue lines are on record. Biotechnology Products and Therapies are the primary driver. The others are education and Certification and cosmetic Products.

Who are REGENE GLOBAL's main competitors?

Direct peers on record are Pluristem Therapeutics, Cytori Therapeutics, Mesoblast, Medipost, Lineage Cell Therapeutics and Athersys. BioXcellerator is listed as an emerging player. Broad incumbents are Galderma and BlueRock Therapeutics. Celltex Therapeutics is listed as a regional player.

Does REGENE GLOBAL have an API?

No public API is recorded for REGENE GLOBAL.

What industry is REGENE GLOBAL in?

REGENE GLOBAL's product category is Regenerative Medicine Biotechnology. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals